BTIG analyst Thomas Shrader raised the firm’s price target on Biohaven to $37 from $28 and keeps a Buy rating on the shares. The BHV-1300 program is a new focus and BTIG sees early data as relatively definitive, the analyst tells investors in a research note. The IND submission for BHV-1300 remains on track by YE23, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BHVN:
- Biohaven price target raised to $36 from $29 at Piper Sandler
- Biohaven reports Q3 adjusted EPS ($1.44), consensus ($1.34)
- Fly Insider: Biohaven, BJ’s Wholesale Club among weeks’ notable insider trades
- Biohaven reported preclinical data from study of taldefgrobep alfa
- Biotech Alert: Searches spiking for these stocks today